Drugs For Neglected Diseasesinitiative North America Inc
Drugs For Neglected Diseasesinitiative North America Inc consistently operates with a surplus and reports no officer compensation.
EIN: 208774179 · New York, NY · NTEE: E05 · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $6.2M |
| Total Expenses | $4.2M |
| Program Spending | 90% |
| Net Assets | $1.1M |
| Transparency Score | 95/100 |
Is Drugs For Neglected Diseasesinitiative North America Inc Legit?
Appears Legitimate
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Drugs For Neglected Diseasesinitiative North America Inc directs 90% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Drugs For Neglected Diseasesinitiative North America Inc
Drugs For Neglected Diseasesinitiative North America Inc (EIN: 208774179) is a nonprofit organization based in New York, NY, classified under NTEE code E05. The organization reported total revenue of $6.2M and total assets of $2.5M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Drugs For Neglected Diseasesinitiative North America Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Drugs For Neglected Diseasesinitiative North America Inc is a mid-size nonprofit that has been operating for 19 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 7.0%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $4.4M |
| Total Expenses | $4.2M |
| Surplus / Deficit | +$179K |
| Total Assets | $1.8M |
| Total Liabilities | $715K |
| Net Assets | $1.1M |
| Operating Margin | 4.1% |
| Debt-to-Asset Ratio | 39.3% |
| Months of Reserves | 5.2 months |
Financial Health Grade: A
In 2023, Drugs For Neglected Diseasesinitiative North America Inc reported a surplus of $179K with revenue exceeding expenses, holds 5.2 months of operating reserves (adequate), has a debt-to-asset ratio of 39.3% (moderate leverage).
Financial Trends
Over 13 years of filings (2011–2023), Drugs For Neglected Diseasesinitiative North America Inc's revenue has grown at a compound annual growth rate (CAGR) of 7.0%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | +10.7% | +8.3% | +57.5% |
| 2022 | -5.3% | -3.5% | -15.8% |
| 2021 | +11.1% | +11.4% | -8.9% |
| 2020 | -19.2% | -21.9% | +11.4% |
| 2019 | -20.8% | -23.8% | -42.0% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 2007 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Drugs For Neglected Diseasesinitiative North America Inc with a Mission Score of 95 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 5%
- programs: 90%
- fundraising: 5%
According to IRS 990 filings, Drugs For Neglected Diseasesinitiative North America Inc allocates its expenses as follows: admin: 5%, programs: 90%, fundraising: 5%. With 90% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a surplus of $179K, with revenue exceeding expenses.
- Debt-to-asset ratio: 39.3%.
Executive Compensation Analysis
Executive compensation is reported as 0% across all available filings, indicating that no officers receive compensation from the organization. This is an exceptional practice, demonstrating a strong commitment to minimizing overhead and maximizing resources for programmatic activities.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Strengths
The following positive indicators were identified for Drugs For Neglected Diseasesinitiative North America Inc:
- Consistent financial surpluses, with revenues generally exceeding expenses (e.g., 2023: $4,350,936 revenue vs. $4,172,304 expenses).
- Zero reported officer compensation across all filings, indicating high efficiency and dedication to mission.
- Steady growth in assets from $216,111 in 2014 to $1,819,761 in 2023, demonstrating financial health.
- Low liabilities relative to assets, suggesting good financial management (e.g., 2023: $715,236 liabilities vs. $1,819,761 assets).
Frequently Asked Questions about Drugs For Neglected Diseasesinitiative North America Inc
Is Drugs For Neglected Diseasesinitiative North America Inc a legitimate charity?
Drugs For Neglected Diseasesinitiative North America Inc (EIN: 208774179) is a registered tax-exempt nonprofit based in New York. Our AI analysis gives it a Mission Score of 95/100. It has 13 years of IRS 990 filings on record. Total revenue: $6.2M. No red flags identified. 4 strengths noted. Financial health grade: A.
How does Drugs For Neglected Diseasesinitiative North America Inc spend its money?
Drugs For Neglected Diseasesinitiative North America Inc directs 90% of its spending to programs and services. Fundraising costs 5%. This exceeds the 65% industry benchmark.
Are donations to Drugs For Neglected Diseasesinitiative North America Inc tax-deductible?
Drugs For Neglected Diseasesinitiative North America Inc is registered as a tax-exempt nonprofit (EIN: 208774179). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What percentage of Drugs For Neglected Diseasesinitiative North America Inc's spending goes to programs?
Drugs For Neglected Diseasesinitiative North America Inc directs 90% to programs, 5% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Drugs For Neglected Diseasesinitiative North America Inc compare to similar nonprofits?
With a transparency score of 95/100 (Excellent), Drugs For Neglected Diseasesinitiative North America Inc is above average for NTEE category E05 nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Drugs For Neglected Diseasesinitiative North America Inc located?
Drugs For Neglected Diseasesinitiative North America Inc is headquartered in New York, New York and files with the IRS under EIN 208774179. It is classified under NTEE code E05.
How many years of IRS 990 filings does Drugs For Neglected Diseasesinitiative North America Inc have?
Drugs For Neglected Diseasesinitiative North America Inc has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $6.2M in total revenue.
Is Drugs For Neglected Diseasesinitiative North America Inc a good charity?
Based on the available financial data, the organization appears to be a very good charity. It consistently operates with a surplus, has growing assets, and notably reports 0% officer compensation, indicating a strong focus on its mission and efficient use of funds.
How has the organization's financial stability changed over time?
The organization has shown consistent financial stability and growth. Revenues have generally outpaced expenses, and assets have steadily increased from $216,111 in 2014 to $1,819,761 in 2023, indicating a healthy financial trajectory.
What is the organization's approach to executive compensation?
The organization reports 0% officer compensation in all available filings, which is an outstanding practice. This suggests a volunteer-led executive team or that executive salaries are covered by a parent organization, allowing more funds to be directed to programs.
Filing History
IRS 990 filing history for Drugs For Neglected Diseasesinitiative North America Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Drugs For Neglected Diseasesinitiative North America Inc's revenue has grown by 126.1%, moving from $1.9M to $4.4M. Total assets increased by 884.2% over the same period, from $185K to $1.8M. Total functional expenses rose by 124.9%, from $1.9M to $4.2M. In its most recent filing year (2023), Drugs For Neglected Diseasesinitiative North America Inc reported a surplus of $179K, with revenue exceeding expenses. The organization holds $715K in liabilities against $1.8M in assets (debt-to-asset ratio: 39.3%), resulting in net assets of $1.1M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $4.4M | $4.2M | $1.8M | $715K | — | — |
| 2022 | $3.9M | $3.9M | $1.2M | $230K | — | View 990 |
| 2021 | $4.2M | $4.0M | $1.4M | $526K | — | View 990 |
| 2020 | $3.7M | $3.6M | $1.5M | $819K | — | — |
| 2019 | $4.6M | $4.6M | $1.4M | $818K | — | View 990 |
| 2018 | $5.8M | $6.0M | $2.3M | $1.8M | — | View 990 |
| 2017 | $4.2M | $4.1M | $1.6M | $866K | — | View 990 |
| 2016 | $3.2M | $3.0M | $795K | $229K | — | View 990 |
| 2015 | $2.9M | $2.6M | $711K | $376K | — | View 990 |
| 2014 | $2.0M | $1.9M | $216K | $104K | — | View 990 |
| 2013 | $2.5M | $2.5M | $164K | $118K | — | View 990 |
| 2012 | $2.3M | $2.4M | $122K | $69K | — | View 990 |
| 2011 | $1.9M | $1.9M | $185K | $35K | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $4.4M, expenses of $4.2M, and assets of $1.8M (revenue +10.7% year-over-year).
- 2022: Revenue of $3.9M, expenses of $3.9M, and assets of $1.2M (revenue -5.3% year-over-year).
- 2021: Revenue of $4.2M, expenses of $4.0M, and assets of $1.4M (revenue +11.1% year-over-year).
- 2020: Revenue of $3.7M, expenses of $3.6M, and assets of $1.5M (revenue -19.2% year-over-year).
- 2019: Revenue of $4.6M, expenses of $4.6M, and assets of $1.4M (revenue -20.8% year-over-year).
- 2018: Revenue of $5.8M, expenses of $6.0M, and assets of $2.3M (revenue +38.8% year-over-year).
- 2017: Revenue of $4.2M, expenses of $4.1M, and assets of $1.6M (revenue +30.7% year-over-year).
- 2016: Revenue of $3.2M, expenses of $3.0M, and assets of $795K (revenue +12.3% year-over-year).
- 2015: Revenue of $2.9M, expenses of $2.6M, and assets of $711K (revenue +44.1% year-over-year).
- 2014: Revenue of $2.0M, expenses of $1.9M, and assets of $216K (revenue -19.6% year-over-year).
- 2013: Revenue of $2.5M, expenses of $2.5M, and assets of $164K (revenue +5.4% year-over-year).
- 2012: Revenue of $2.3M, expenses of $2.4M, and assets of $122K (revenue +22.0% year-over-year).
- 2011: Revenue of $1.9M, expenses of $1.9M, and assets of $185K.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Drugs For Neglected Diseasesinitiative North America Inc:
Data Sources and Methodology
This transparency report for Drugs For Neglected Diseasesinitiative North America Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.